Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
53.00 ^USD	+0.33%		+3.82%	+37.31%

07-07	Protagonist Therapeutics, Inc. - Special Call
06-17	Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	MT

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating

Published on 2025-03-10 at 09:53, updated on 2025-03-10 at 09:54

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. - Special Call	07-07
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	06-17	MT
Protagonist Therapeutics, Inc. - Special Call	06-16
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT
J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study	05-09	RE
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study	05-09	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA	03-20	RE
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	03-11	MT
Sector Update: Health Care Stocks Decline Late Afternoon	03-10	MT
Top Midday Gainers	03-10	MT
Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra	03-10	DJ
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	03-10	MT
Protagonist, Johnson & Johnson Say Phase 2b Icotrokinra Study Meets Primary Endpoint in Ulcerative Colitis	03-10	MT
Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis	03-10	CI
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera	03-03	MT
Protagonist Therapeutics, Inc. - Special Call	03-03
Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide	03-03	RE
Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera	03-03	CI
Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M	02-21	MT
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98	02-21	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-21	CI

Chart Protagonist Therapeutics, Inc.

Duration

Period

PTGX: Dynamic Chart

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Employees

124

Sector

Biotechnology & Medical Research

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company